Efficacy of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Secondary Outcomes from the ACT 2 Randomized Controlled Trial

Read full text Summarise with VIRAT
Authors: Carla J. Chibwesha, Nicholas S. Teodoro, Katie R. Mollan, Jessica Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Lisa Rahangdale
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: We report secondary histologic and high-risk HPV (hrHPV) outcomes from the Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living with HIV (ACT 2) Trial. Methods: We conducted a double-blind Phase 2b feasibility trial of loop electrosurgical excision procedure (LEEP) combined with adjuvant intravaginal 5-fluorouracil (5FU) cream. Women living with HIV (WLWH) and cervical intraepithelial neoplasia (CIN) 2/3 underwent LEEP and were randomly assigned (1:1) to receive 8 doses of 5FU or placebo cream. Our secondary outcomes were (a) regression of cervical disease and (b) clearance of hrHPV. Results: From March 2023 to January 2025, 180 participants underwent LEEP and were randomized to 5FU or placebo cream. Median age was 41 years (IQR: 35-45), 29% had HPV16, 18% had HPV18/45; 99% of women were virologically suppressed (

Fields of Study & Subjects

Cervical Cancer and HPV Research Reproductive tract infections research Genital Health and Disease

Publication details

Journal / source
medRxiv
Publication date
22 March 2026
Language
EN
Document type
Preprint